Monoclonal antibodies are characterized by their vast diversity in both structure and activity. As such, researchers may evaluate hundreds of mAbs while identifying their best binders. But this selection process can take months as conventional techniques for biologics discovery do not include tools that can truly assess mAb biophysical diversity that directly affects specificity and affinity. With next generation protein sequencing (NGPS), mAb leads can be analyzed down to the amino acid level for targeted and controlled development in parallel.
Polyclonal antibodies are well used in drug discovery research because they recognize and bind many different epitopes of a single antigen; however, polyclonal mixtures are difficult to work with due to the lack of information of each antibody in the mixture. pAb sequencing allows direct access to high-affinity antibodies from the native immune response, deriving their amino acid sequences, which can be expressed as a set of mAbs that perform as well or better than the original polyclonal mixture. pAb sequencing is the most direct method for therapeutic antibody discovery.